FGEN FibroGen Inc

34.12
-1.78  -5%
Previous Close 35.9
Open 37.1
Price To Book 5.81
Market Cap 3,002,553,312
Shares 87,999,804
Volume 649,024
Short Ratio
Av. Daily Volume 718,465
Stock charts supplied by TradingView

NewsSee all news

  1. FibroGen Reports Fourth Quarter and Full Year 2019 Financial Results

    Roxadustat NDA submission accepted with PDUFA date of December 20, 2020Pamrevlumab pivotal trials for treatment of idiopathic pulmonary fibrosis (IPF) and locally advanced unresectable pancreatic cancer (LAPC)

  2. FibroGen to Report Fourth Quarter and Full Year 2019 Financial Results

    SAN FRANCISCO, Feb. 18, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) will announce its fourth quarter and full year 2019 financial results after market close on Monday, March 2, 2020. FibroGen will also

  3. FibroGen Announces U.S. FDA Acceptance of New Drug Application for Roxadustat for the Treatment of Anemia of Chronic Kidney Disease

    SAN FRANCISCO, Feb. 11, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that the U.S. Food and Drug Administration (FDA) has completed its filing review of its New Drug Application (NDA) for

  4. FibroGen to Present at 9th Annual SVB Leerink Global Healthcare Conference

    SAN FRANCISCO, Feb. 11, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) will participate in the 9th Annual SVB Leerink Global Healthcare Conference on February 25, 2020. Enrique Conterno, Chief Executive Officer,

  5. Astellas Submits Supplemental New Drug Application for Approval of Evrenzo® (roxadustat) for the Treatment of Anemia Associated with Chronic Kidney Disease in Non-Dialysis Dependent Patients in Japan

    TOKYO and SAN FRANCISCO, Jan. 30, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (NASDAQ:FGEN, CEO: Enrique Conterno, ",

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

PDUFA date December 20, 2020.
Roxadustat
Anaemia in Chronic Kidney Disease
Phase 3 data due 2021.
Roxadustat
Myelodysplastic syndromes (MDS)
Phase 3 trial to be initiated 2H 2020.
Pamrevlumab FG-3019
Duchenne muscular dystrophy
Phase 3 trial initiation announced July 22, 2019.
Pamrevlumab (FG-3019) - ZEPHYRUS
Idiopathic pulmonary fibrosis
Phase 3 initiation of dosing announced October 23, 2019.
Pamrevlumab (FG-3019)
Pancreatic cancer
Phase 2 trial initiation announced September 26, 2019.
Roxadustat
Chemotherapy-induced anemia (CIA)

Latest News

  1. FibroGen Reports Fourth Quarter and Full Year 2019 Financial Results

    Roxadustat NDA submission accepted with PDUFA date of December 20, 2020Pamrevlumab pivotal trials for treatment of idiopathic pulmonary fibrosis (IPF) and locally advanced unresectable pancreatic cancer (LAPC)

  2. FibroGen to Report Fourth Quarter and Full Year 2019 Financial Results

    SAN FRANCISCO, Feb. 18, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) will announce its fourth quarter and full year 2019 financial results after market close on Monday, March 2, 2020. FibroGen will also

  3. FibroGen Announces U.S. FDA Acceptance of New Drug Application for Roxadustat for the Treatment of Anemia of Chronic Kidney Disease

    SAN FRANCISCO, Feb. 11, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that the U.S. Food and Drug Administration (FDA) has completed its filing review of its New Drug Application (NDA) for

  4. FibroGen to Present at 9th Annual SVB Leerink Global Healthcare Conference

    SAN FRANCISCO, Feb. 11, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) will participate in the 9th Annual SVB Leerink Global Healthcare Conference on February 25, 2020. Enrique Conterno, Chief Executive Officer,

  5. Astellas Submits Supplemental New Drug Application for Approval of Evrenzo® (roxadustat) for the Treatment of Anemia Associated with Chronic Kidney Disease in Non-Dialysis Dependent Patients in Japan

    TOKYO and SAN FRANCISCO, Jan. 30, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (NASDAQ:FGEN, CEO: Enrique Conterno, ",

  6. FibroGen Names Enrique Conterno as Chief Executive Officer

    SAN FRANCISCO, Jan. 06, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) announced that its Board of Directors unanimously appointed Enrique Conterno as the company's Chief Executive Officer and a member of the

  7. FibroGen Submits New Drug Application to the U.S. FDA for Roxadustat in Patients With Anemia of Chronic Kidney Disease

    SAN FRANCISCO, Dec. 23, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for roxadustat for the

  8. FibroGen Announces Roxadustat Inclusion in China's National Reimbursement Drug List

    SAN FRANCISCO, Dec. 02, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today reported roxadustat has been included on the updated National Reimbursement Drug List (NRDL) released by China's National Healthcare

  9. HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors to Contact Its Attorneys, Firm Investigating Possible Securities Fraud

    SAN FRANCISCO, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Hagens Berman urges FibroGen, Inc. (NASDAQ:FGEN) investors who have suffered significant losses to submit their loss now to learn if they qualify to recover their

  10. Glancy Prongay & Murray LLP Announces Investigation on Behalf of FibroGen, Inc. Investors

    Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) investors concerning the Company and its officers' possible violations of federal securities laws.

  11. INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of FibroGen, Inc. Investors

    Law Offices of Howard G. Smith announces an investigation on behalf of FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) investors concerning the Company and its officers' possible violations of federal securities laws.

  12. FibroGen Reports Third Quarter 2019 Financial Results

    Roxadustat Positive Pooled Phase 3 Efficacy and Cardiovascular Safety Data Presented Last Friday at American Society of Nephrology 2019 Kidney WeekPlan to Submit Roxadustat U.S. NDA This Quarter Conference Call Today at

  13. FibroGen Announces Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease

    Roxadustat cardiovascular safety comparable to placebo in non-dialysis dependent (NDD) patients, as assessed by Major Adverse Cardiovascular Events (MACE) and MACE+ Roxadustat did not increase risk of MACE and reduced

  14. FibroGen Presents Phase 3 Efficacy and Safety Results for Roxadustat Versus Epoetin Alfa as Treatment of Anemia in Incident Dialysis Patients with Chronic Kidney Disease

    WASHINGTON, Nov. 07, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), today announced results from the Phase 3 HIMALAYAS trial evaluating roxadustat for the treatment of anemia in incident dialysis (ID) patients

  15. HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors to Contact Its Attorneys Now, Firm Investigating Possible Securities Fraud

    SAN FRANCISCO, Nov. 5, 2019 /PRNewswire/ -- Hagens Berman urges FibroGen, Inc. (NASDAQ:FGEN) investors who have suffered significant losses to submit their loss now to learn if they qualify to recover their investment

  16. FibroGen, Inc. Investigated by Block & Leviton LLP For Violations of Federal Securities Laws

    BOSTON, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors and whistleblowers nationwide, is investigating FibroGen, Inc. (NASDAQ:FGEN) and

  17. FibroGen To Report Third Quarter 2019 Financial Results on Monday, November 11, 2019

    SAN FRANCISCO, Nov. 04, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), today announced that financial results for the third quarter 2019 will be released after market on Monday, November 11, 2019. An investor

  18. FibroGen Announces First Patient Dosed in LAPIS, a Phase 3 Clinical Trial of Pamrevlumab for the Treatment of Patients With Locally Advanced Pancreatic Cancer

    SAN FRANCISCO, Oct. 23, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), today announced the dosing of the first patient in the LAPIS Phase 3 clinical study of pamrevlumab in patients with unresectable locally

  19. Roxadustat Global Phase 3 Results for Treatment of Chronic Kidney Disease (CKD) Anemia to be Presented at American Society of Nephrology Kidney Week 2019

    SAN FRANCISCO, Oct. 11, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), today announced that results from the global Phase 3 roxadustat clinical program will be presented at the American Society of Nephrology

  20. FibroGen Congratulates Dr. William G. Kaelin, Jr., Scientific Advisory Board Member, on Receipt of the 2019 Nobel Prize in Physiology or Medicine

    SAN FRANCISCO, Oct. 07, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) is pleased to announce that William G. Kaelin, Jr., who serves on the company's Scientific Advisory Board, has been awarded the 2019 Nobel

  21. FibroGen Receives One of China Pharmaceutical Industry's Highest Awards for Clinical Innovation for Roxadustat

    SAN FRANCISCO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that roxadustat received the 2019 Dushu Lake Prize 独墅湖杯in China for "On-Market Innovative Drug with Highest Clinical

  22. FibroGen Announces Publication in the Lancet Respiratory Medicine of Positive Pamrevlumab Efficacy and Safety Data for the Praise Phase 2 Study in Idiopathic Pulmonary Fibrosis

    -- Novel Human Antibody Targets CTGF, A Central Mediator in Fibrosis -- SAN FRANCISCO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced publication in The Lancet Respiratory Medicine of

  23. FibroGen Announces Initiation of Phase 2 Clinical Trial of Roxadustat for the Treatment of Anemia in Cancer Patients Receiving Chemotherapy

    SAN FRANCISCO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced first patient dosed in the company's Phase 2 clinical study of roxadustat, a first-in-class hypoxia-inducible factor prolyl

  24. Roxadustat Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients

    SAN FRANCISCO and TOKYO, Sept. 20, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN, Interim CEO: James A. Schoeneck, "FibroGen")) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.,

  25. Evrenzo® (roxadustat) Tablets Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients

    TOKYO and SAN FRANCISCO, Sept. 20, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (NASDAQ:FGEN, Interim CEO: James A Schoeneck.,

  26. Fibrogen Announces Passing of CEO Thomas B. Neff, Scientific Innovator and Pioneering Biopharmaceutical Executive

    SAN FRANCISCO, Aug. 26, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) announced today that Thomas B. Neff, Chief Executive Officer and Chairman of the Board of Directors of FibroGen, passed away unexpectedly